Author

F. Ferron

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Assay:structural biology· 2 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:protein folding & dynamics· 1 Assay:proteomics· 1

Frequent Co-Authors

B. Canard· 5 shared E. Decroly· 3 shared M. Feracci· 3 shared A. Moussa· 2 shared A. Shannon· 2 shared B. Selisko· 2 shared J.-P. Sommadossi· 2 shared K. ALVAREZ· 2 shared

Activity by Year

2019-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 42 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersBiochemistry

B. Canard

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

The activation chain of the broad-spectrum antiviral bemnifosbuvir at atomic resolution

A. Chazot, C. Zimberger, M. Feracci, A. Moussa, S. Good, J.-P. Sommadossi, K. ALVAREZ, F. Ferron, B. Canard

This paper reveals the activation pathway of bemnifosbuvir to its active form AT-9010, showing the required enzymes and structural insights into the process.

bioRxiv · Feb 16, 2024 · PreprintBiochemistry

A high-throughput fluorescence polarization assay to discover inhibitors of arenavirus and coronavirus exoribonucleases

S. G. Hernandez Tapia, M. Feracci, C. T. De Jesus, P. El-Kazzi, R. Kaci, L. Garlatti, E. Decroly, B. Canard, F. Ferron, K. Alvarez

This paper develops a high-throughput fluorescence polarization assay to screen inhibitors of exoribonucleases from arenaviruses and coronaviruses and validates it with a small compound library.

bioRxiv · Apr 2, 2021 · PreprintBiochemistry

Protein-primed RNA synthesis in SARS-CoVs and structural basis for inhibition by AT-527

A. Shannon, V. Fattorini, B. Sama, B. Selisko, M. Feracci, C. Falcou, P. Gauffre, P. El Kazzi, E. Decroly, N. Rabah, K. Toulon, C. Eydoux, J.-C. Guillemot, M. Noel, F. Debart, , B. Canard

This paper identifies a protein-priming mechanism for SARS-CoV RNA synthesis and shows that AT-527 inhibits this process by targeting both NiRAN and RdRp domains.

bioRxiv · Mar 23, 2021Biochemistry

Favipiravir strikes the SARS-CoV-2 at its Achilles heel, the RNA polymerase

A. Shannon, B. Selisko, T.-T.-N. Le, J. Huchting, F. Touret, G. Piorkowski, V. Fattorini, F. Ferron, E. Decroly, C. Meier, B. Coutard, O. Peersen, B. Canard

This study shows Favipiravir inhibits SARS-CoV-2 by targeting its RNA polymerase through chain termination, slowed synthesis, and mutagenesis.

bioRxiv · May 15, 2020 · PreprintBiochemistry

Arenaviridae exoribonuclease presents genomic RNA edition capacity.

E. Yekwa, C. Aphibanthammakit, X. Carnec, C. Picard, B. Canard, S. Baize, F. Ferron

This paper investigates the RNA exonuclease activity of Arenavirus ExoN, showing it edits genomic RNA and links to genome stability rather than innate immune suppression.

bioRxiv · Feb 13, 2019 · PreprintBiochemistry